A naphylaxis is at least as old as the sphinx. One of the first cases of death attributed to anaphylaxis was documented in Egyptian hieroglyphics in 2641 BC, which depicted Pharaoh Menes dying after a sting by a hornet or wasp. 1 Several millennia later, in 1902, two French physiologists, Charles R. Richet and Paul J. Portier, first described anaphylaxis in the scientific literature. This was a serendipitous discovery that occurred while they were investigating the toxins produced by jellyfish and sea anemone. They attempted to determine if tolerance or immunity to the toxins could be achieved through repeated injections. They noted that dogs previously injected with fluid from these sea creatures suffered a rapid death after a subsequent smaller injection. Richet initially proposed the term ''aphylaxis,'' derived from the Greek language-''a'' meaning contrary to and ''phylaxis'' meaning protection, to describe this phenomenon. Because it lacked euphoric expression, it was changed to anaphylaxis. Almost 10 years later, Richet received the Nobel Prize in Medicine for this discovery and his subsequent work on anaphylaxis. This work paved the way for the development of immunotherapy. 2 Shortly after the discovery of Richet and Portier, there were cases of anaphylaxis-related deaths reported in the literature, two after food challenges in infants. 3 
DEFINITION
There is no universal agreement on the definition of anaphylaxis. However, in 2006, the Second Symposium on the Definition and Management of Anaphylaxis recommended the following definition: ''Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. '' 4 Anaphylaxis and anaphylactoid reactions are life-threatening allergic conditions requiring immediate intervention. Isolated urticarial reactions are not anaphylactic reactions. Anaphylaxis involves an immunoglobulin E (IgE) -mediated immediate hypersensitivity reaction resulting in the release of potent chemical mediators from mast cells and basophils. Anaphylactoid reactions are non-IgE-mediated but are clinically indistinguishable from anaphylaxis. 5 Although nearly every organ system can be affected by an anaphylactic reaction, most effects involve the cutaneous, respiratory, cardiovascular, and gastrointestinal systems. Recognition and early treatment of anaphylaxis are paramount in reducing patient mortality and morbidity. 6, 7 
EPIDEMIOLOGY
Accurate data regarding pediatric anaphylaxis in the United States remain elusive, and estimates of incidence vary widely. This is due to many factors including insufficient studies in the pediatric population, lack of standardized International Classification of Diseases coding and consensus regarding the definition of anaphylaxis, and failure to report serious and fatal events. 6 In 2004, Bohlke et al 8 estimated the incidence of physician-diagnosed anaphylaxis among children and adolescents to be 10.5 episodes per 100,000 person-years. This is lower than the overall population incidence reported by Yocum et al 9 in 1999 of 21 per 100,000 person-years. A report from 2001 estimated that anaphylaxis might affect 1.2% to 16.8% of the total US population and that 0.002% of the population may die of anaphylaxis. In the United States, deaths due to anaphylaxis are estimated to be 1500 per year-the majority of which (1300) are drug induced (including radiographic contrast media). This is followed by food-and sting-related causes, each resulting in approximately 100 deaths per year. 7 Several studies have indicated that the United States has a higher incidence of anaphylaxis compared with other countries. Reasons for this include expansion of the American diet, increased use of peanuts in foods, and the widespread use of latex gloves. 3, 7, 10, 11 Children and adolescents with atopy, including asthma, eczema, and allergic rhinitis, are at higher risk of anaphylaxis. 8,10,12 -14 The severity of a previous reaction does not necessarily predict the severity of a subsequent reaction. 10, 15 Certainly, individuals with a previous anaphylactic reaction are at higher risk for recurrence. 6, 8, 12, 16 Some studies indicate a male predominance in children. 16 -19 Genetic or racial disposition has not been shown to be a risk factor. 17 
ETIOLOGY
The most common causes of anaphylaxis in children are foods, followed by medications, Hymenoptera envenomation, blood products, immunotherapy, latex, vaccines, and radiographic contrast media. 8, 16, 20 Exercise-induced and idiopathic anaphylaxis are described in the adult literature but rarely occur in young children (Table 1) . 16, 18, 19, 21 Food is also the leading cause of all anaphylactic reactions treated in emergency departments across the United States. 22 Children can outgrow many food allergies, such as milk, eggs, and soybean allergies. 15 However, persistent sensitivity is seen more commonly with peanuts, tree nuts, and shellfish. These latter foods are also most often implicated in fatal or nearfatal reactions. 22 Types of foods implicated in anaphylaxis vary depending on geographic regions. In the United States, peanuts are the most common cause of food-induced anaphylaxis in children. In Australia, eggs, peanuts, and dairy products are most commonly implicated in food-related anaphylaxis; in Italy, it seems to be shellfish and dairy products. Shellfish allergy is common in Southeast Asian countries. 18, 19, 23 Medications and hymenoptera envenomation account for most of the cases of childhood anaphylaxis unrelated to food. Penicillin, cross-reactive drugs to penicillin, and nonsteroidal anti-inflammatory drugs are the most common medications implicated in drug-associated anaphylaxis in children. 8, 19 Penicillin-allergic individuals have a 4% to 10% risk of an allergic reaction to a cephalosporin. 5, 20 Some medications contain food-related substances. For instance, propofol (Diprivan), an anesthetic agent used for adult and pediatric anesthesia and sedation, contains egg and soy constituents. This medication would be contraindicated for the child with allergy to either of these foods. The specific type of antigen exposure is not necessarily related to the rapidity of the onset of symptoms. Route of exposure may be important. For example, parenterally injected medication and hymenoptera envenomation tend to result in very rapid development of anaphylactic symptoms. However, foods have also been reported to elicit symptoms less than 1 minute from time of exposure. 6, 12 Anaphylaxis to immunizations is estimated to be approximately 1.5 events per 1 million administrations. 24 The most common immunizations implicated are measles, mumps, and rubella (MMR); influenza; diphtheria; pertussis; tetanus; and rabies. Both MMR and influenza vaccines are prepared using chick-derived cells; however, MMR vaccine is manufactured using a different cell type resulting in insignificant amounts of egg cross-reacting proteins. The American Academy of Pediatrics currently recommends giving MMR vaccine to children with known egg sensitivity; however, egg-related allergy remains a contraindication to receiving influenza vaccine. 25 Anaphylaxis associated with latex allergy is seen more commonly in children with spina bifida, urogenital defects, and associated multiple surgeries. 21 This is likely due to repetitive exposure to latex antigens. Increased awareness and use of latex-free products and low-powder, low-protein gloves can help prevent anaphylaxis in latex-sensitive children. 6 
PATHOPHYSIOLOGY
Classically, the IgE-mediated hypersensitivity reaction has been used to describe anaphylaxis. Allergens are introduced into the body via many different mechanisms, including ingestion, parenteral, inhalation, or direct contact. The first time a person is exposed to an antigen, specific IgE antibodies are formed in response to the foreign antigen. These antibodies bind to the high-affinity Fc receptors on tissue mast cells and blood basophils. Upon subsequent exposure to the antigen, epithelial or endothelial barriers are breached, allowing the antigen access to the IgE antibodies on the presensitized mast cells or basophils. Binding of the antigen to the IgE antibodies causes these molecules to bridge, stimulating degranulation of the mast cells and basophils. Subsequently, a rapid and massive release of potent preformed chemical mediators occurs. Histamine is the predominate chemical released. Other mediators involved include prostaglandin D2, leukotrienes, platelet-activating factor, tryptase and eosinophil and neutrophil chemotactic factors. It is through these potent chemicals that the symptoms of anaphylaxis are manifest, including increased 
BIPHASIC REACTIONS
Delayed reactions, developing as late as 72 hours after the initial reaction, occur in children. In a recent review of children admitted to the hospital for anaphylaxis, 6% had a biphasic reaction, with asymptomatic intervals ranging between 1.3 and 28.4 hours. 16 Higher rates, up to 23%, have been reported in children. 12 In 2005, Lieberman 26 performed an extensive review of the literature for the last 35 years, specifically investigating biphasic reactions. The overall incidence was highly variable, ranging from 1% to 20% of all anaphylactic reactions. Failure to administer adequate doses of epinephrine promptly increases the risk of a biphasic reaction. 12, 16, 26 However, route, quantity, and type of antigen exposure are not correlated with an increased likelihood of a latent reaction. Symptoms and severity during an initial reaction are not necessarily predictive of the occurrence or symptoms experienced during a latent-phase reaction. 17, 27 The role of corticosteroids in preventing biphasic reactions remains unclear; however, many reports have found them to be ineffective.
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DIAGNOSIS
The diagnosis of anaphylaxis is largely based on clinical findings. A specific trigger may not be known at the time of presentation; however, the majority can be identified through a complete history and/or subsequent immunologic testing. In 1997, a pediatric anaphylaxis report conducted for a 5-year period demonstrated that 69% of the children who had an anaphylactic reaction had no history of allergy to the causative agent. 30 The spectrum, severity, and onset of symptoms are highly variable. Individual sensitivity, route, quantity, and rate of administration of the antigen determine patient response. 24 Symptoms can occur in as little as seconds or rarely several hours after exposure to an antigen. In children, most symptoms occur within 5 to 30 minutes postexposure. 12, 16, 19 In general, parenteral administration of antigen and envenomations are associated with shorter latency periods (seconds to minutes). However, food exposure, especially in sensitive individuals, can elicit a similarly brief latency period.
Most (80% -90%) children will experience cutaneous symptoms, although they may be transient and not apparent upon presentation to the emergency department. These include flushing, pruritus, urticaria, diaphoresis, sensation of warmth, and angioedema. Respiratory symptoms are present in up to 94% of the children. Among the most common symptoms are throat tingling or pruritus, hoarseness, stridor, chest or throat tightness, wheezing, hypoxemia, and dyspnea. Gastrointestinal symptoms can be prominent, occurring in approximately 10% to 46% of the children. Food reactions are often associated with gastrointestinal symptoms. 30 Nausea, vomiting, diarrhea, and cramping are frequently reported. Cardiovascular symptoms are not infrequent (~30%) and include arrhythmias, diminished perfusion, and hypotension. Myocardial infarction and cardiac arrest have been reported. Cardiovascular collapse is a common prearrest finding and is caused by an absolute and relative hypovolemia, secondary to increased capillary permeability and vasodilation. 31 Within 10 minutes, the circulating blood volume can decrease by 35% during anaphylaxis. 32 Other symptoms include an impending sense of doom (angor animi), dizziness, uterine cramps, visual disturbances, metallic taste, syncope, and seizure (Table 2) . 12, 16, 18, 19, 27 In February of 2006, the participants of the Second Symposium on the Definition and Management of Anaphylaxis developed a set of clinical criteria for diagnosing anaphylaxis which they believed would likely capture greater than 95% of the cases of anaphylaxis. Table 3 is adapted from their original criteria. 4 
LABORATORY EVALUATION
In the acute management of anaphylaxis, ancillary laboratory testing is not indicated. If there is uncertainty about the diagnosis of anaphylaxis, significantly elevated serum tryptase levels may be helpful. 33 Histamine and b-tryptase are the major known components released during mast cell degranulation, whereas a-tryptase is secreted by resting mast cells. 34, 35 Basophils contain an abundance of histamine but negligible amounts of tryptase. 36 The collection and measurement of histamine levels is fraught with difficulty, limiting its use in aiding in the diagnosis of anaphylaxis. 34 Histamine has a narrow window for detection of abnormalities; it peaks in 5 to 10 minutes and declines rapidly, and it is back to baseline within 15 to 60 minutes. In contrast, tryptase samples are easy to collect, and commercial assays are readily available. Tryptase peaks in 1 to 2 hours and has a half-life of approximately 2 hours. Unfortunately, However, caution is advised when relying on tryptase levels to exclude or confirm a diagnosis of anaphylaxis. Several studies have demonstrated low sensitivity (0.20 -0.55) for serum tryptase in diagnosing anaphylaxis. 4, 34 Sensitivity was increased to 0.73 when serial tryptase measurements showed an increase of 2.0 mg/L or greater. 33 In addition, antigen-induced systemic anaphylaxis has been demonstrated in mast cell -deficient mice. 37, 38 Lastly, healthy individuals not experiencing any form of an allergic reaction have demonstrated total serum tryptase levels higher than the manufacturer's upper limit of normal value. 34 Therefore, caution is advised when interpreting tryptase levels.
The differential diagnosis of anaphylaxis in children includes vasovagal reaction, hereditary angioedema, panic attack, urticaria pigmentosa, seizure, vocal cord dysfunction, systemic mastocytosis, status asthmaticus, croup, tracheitis, supraglottitis, pheochromocytoma, or obstructive upper airway foreign body.
MANAGEMENT AND TREATMENT
Appropriate management of a life-threatening anaphylactic reaction involves simultaneous evaluation of the patient and rapid administration of epinephrine. The patient should be placed on a continuous cardiopulmonary monitor, including pulse oximetry. Supine positioning with leg elevation may be helpful if signs of shock are present, unless precluded by dyspnea or emesis. 39 Immediate attention should be given to airway, breathing, and circulation. If the airway is patent, oxygen should be administered via a nonrebreather face mask at 12 to 15 L/min initially, then reduced according to need. Early consultation with anesthesia is warranted. If there is airway compromise, endotracheal intubation should be performed immediately. Cricothyrotomy may be necessary. Consider early elective intubation for the patient with significant hoarseness and lingual or oropharyngeal edema. These conditions may progress rapidly, and intubation may be technically difficult, given the degree of edema. Therefore, sedated intubation without paralysis may be warranted. 6, 24, 31 Immediate administration of an adequate dose of epinephrine is critical to decreasing patient morbidity and mortality. 12 Although epinephrine has a narrow therapeutic index (risk-benefit ratio), it has important a 1 , b 1 , and b 2 agonist actions that play a key role in reversing symptoms of anaphylaxis. The critical a 1 effects include increasing peripheral vascular resistance by promoting vasoconstriction and decreasing mucosal edema. Increased inotropy and chronotropy are b 1 -agonist effects. Stimulation of the b 2 receptors causes increased bronchodilation and decreased release of mast cell and basophil mediators. 40 Historically, the subcutaneous route of administration has been anecdotally advised. However, well-designed studies have concluded that, in both children and adults, the intramuscular route of delivery is superior to the subcutaneous route in achieving significantly faster and higher peak plasma concentrations. This is likely due to decreased perfusion of the skin in an attempt to maintain systemic blood pressure during anaphylaxis. The anterolateral thigh is the recommended site of injection. 41, 42 Epinephrine concentration of 1:1000 is used for intramuscular administration at a dose of 0.01 mg/kg (0.01 mL/kg), with a maximum dose of approximately 0.3 mg (0.3 mL). If the initial dose is ineffective, it may be repeated at 5-to 15-minute intervals. The 1:1000 solution is not indicated for intravenous use.
Inhaled epinephrine should not be given in lieu of intramuscular epinephrine in the acute management of anaphylaxis in children. Investigators determined that children were ineffective at inhaling sufficient amounts of epinephrine using a metered dose inhaler despite expert coaching. 43 As an alternative to intramuscular injection, the sublingual route of epinephrine administration has recently been investigated using a rabbit model. Although the results are promising, there is insufficient data to recommend its routine use in the treatment of anaphylaxis in humans. 44 Crystalloid fluid should be administered early. A rapid bolus of 20 mL/kg should be given and repeated as necessary. The hypotensive patient should be placed in Trendelenburg position. If hypotension persists, despite positioning, aggressive fluid resuscitation, and intramuscular epinephrine, intravenous epinephrine should be administered. It should be given intravenously or intraosseous as a 1:10,000 solution at 0.01 mg/kg (0.1 mL/kg), with a maximum dose of 1 mg. A continuous epinephrine infusion may be necessary to maintain blood pressure. If hypotension Table 3 for diagnostic criteria. yManage cardiac dysrhythmias per PALS guidelines. zHigh-flow oxygen via a nonrebreather should be administered initially then titrated to the need of the patient. xSupine positioning with leg elevation and Trendelenberg positioning should be avoided if the patient is experiencing dyspnea or emesis. kIntramuscular epinephrine should not be delayed; it should be given immediately after the patient is placed on a CR monitor. {Continuous infusion of epinephrine is with the 1:10,000 solution starting at 0.1 mg/kg per minute up to 1 mg/kg per minute. Other vasopressors to consider include: dopamine, vasopressin, and norepinephrine. #Glucagon should be given to the hypotensive patient who is taking b-blockers. Ensure good airway protection as glucagon frequently causes emesis. The intravenous dose for children weighing 20 kg or less is 0.02 to 0.03 mg/kg up to 0.5 mg/dose; for children weighing greater than 20 kg give 1 mg/dose. **Diphenhydramine is the intravenous H1 antihistamine of choice. The pediatric dose is 1.25 mg/kg per dose up to 50 mg per dose. Ranitidine (0.5 -1 mg/kg up to 50 mg per dose) is an H2 antihistamine that can be given intravenously with established pediatric use. yyMethylprednisolone succinate is the preferred intravenous corticosteroid and can be given as 1 to 2 mg/kg, up to a maximum of 125 mg. Note: Doses indicated are for children; neonate and adult doses may differ. Refer to a pediatric drug handbook for guidelines and restrictions regarding medication administration. IO indicates intraosseous; NS, normal saline; LR, lactated ringers.
n 2007 Lippincott Williams & Wilkins continues despite the above-mentioned interventions, vasopressin or other potent vasopressors (a 1 agonists) may be more effective. 4, 5, 45, 46 Glucagon has positive inotropic, chronotropic, and vasoactive properties independent of the b-receptor and should be considered for the persistently hypotensive patient who is taking b-blockers.
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Inhaled b 2 -agonist therapy can be helpful for patients with bronchospasm and should be initiated promptly in these individuals. This is particularly important for individuals with asthma. 5 Second-line or adjunctive agents include H 1 and H 2 antihistamines and corticosteroids. It is important to realize that antihistamines have a slow onset of action and cannot block events that occur subsequent to histamine receptor binding. Administration of H 1 and H 2 antihistamines in combination has been reported to be more effective than H 1 antihistamines alone in improving some of the manifestations of anaphylaxis. 47 Diphenhydramine, a first generation H 1 antihistamine, can be given parenterally and is most frequently used in the management of anaphylaxis. Secondgeneration H 1 antihistamines (eg, loratadine and cetirizine)
are not yet available for parenteral administration; therefore, they have little use in the acute management of anaphylaxis. Ranitidine, an H 2 antihistamine, has well-established parenteral and oral dosages for children. 47, 48 The use of corticosteroids in anaphylaxis has never been determined in clinical trials. They have been incorporated into the management of anaphylaxis because of their usefulness in other allergic diseases but are not likely to be helpful in the acute management stage. They may be most helpful for the patient with a history of recent corticosteroid use, asthma, or endogenous corticosteroid deficiency. Their effectiveness in preventing biphasic reactions has not been established. 4, 17 A period of observation is indicated for all patients experiencing an anaphylactic reaction. Latent reactions can occur in up to 20% of the patients and can rarely occur as late as 72 hours after the initial reaction. 26 The length of time for observation should be based on the severity of the initial reaction, adequacy of supervision, reliability of the patient/ parent, and ease of access to medical care. Many authors suggest an observation time of 6 to 8 hours, but an observation time of up to 24 hours may be warranted for some patients. High-risk patients include those who have a history of a previous biphasic reaction, asthma, and the possibility of continuing absorption of antigen or who presented with severe or refractory symptoms. 4, 49 Figure 1 illustrates an algorithm for the treatment and management of pediatric anaphylaxis.
OUTPATIENT MANAGEMENT AND PREVENTION
All patients being discharged after experiencing an anaphylactic reaction need to have general anaphylaxis education and an emergency anaphylaxis action plan in place. All caregivers of the child should have a copy and a good understanding of this care plan, including childcare facilities and schools. This includes prescription of an epinephrine autoinjector. Parents and patients should receive information regarding indications for the use of the autoinjector and directions for administration. Childcare facilities, other caregivers, and appropriate school personnel should have an epinephrine autoinjector for the child and be familiar with the indications for use and technique of administration. 50 Currently, there are only 2 fixed doses of self-injectable epinephrine (1:1000), 0.15 mg and 0.30 mg. The most widely known autoinjector is the EpiPen (0.30 mg) (Dey LP, Napa, Calif ) and EpiPen Jr (0.15 mg). EpiPen is packaged in a single or a 2-pak device, both with trainer injectors. Twinject (Verus Pharmaceuticals Inc, San Diego, Calif ), also a 2-dose device, is available in both the 0.15-mg and 0.30-mg doses. However, in this system, the same needle is used for the second dose after disassembly of the device. Moreover, it does not come with a trainer device. Having 2 doses of epinephrine readily available is advised because second injections have been necessary in up to 36% of the patients experiencing anaphylaxis. 40, 51 The chosen dose should be nearest to 0.01 mg/kg per dose. The 0.30-mg dose found in EpiPen has been shown to raise the systolic blood pressure significantly and causes more adverse events when compared with that of EpiPen Jr (0.15 mg). 52 Prescribing out-of-hospital epinephrine to children weighing less than 10 kg can be problematic, given the lack of appropriately dosed autoinjectors. A study in 2001 evaluated the ampule/syringe/needle method for epinephrine administration in the out-of-hospital setting for infants. Investigators found that parents were unable to rapidly draw up an accurate dose of epinephrine. They also found that although health care providers could draw up the dose rapidly, accuracy was poor. 53 Pharmacy predrawn doses for infants may also be problematic. Infants weighing less than 10 kg with a history of anaphylaxis are recommended to receive the 0.15 mg-dose autoinjector for outof-hospital use until smaller-dosed autoinjectors become available. 40 Consultation with a pediatric allergist is imperative in this circumstance. Parents should be advised that epinephrine degrades over time and exposure to heat, cold and sunlight will hasten degredation. Prescriptions must be refilled annually.
The child and their parent should receive information regarding the avoidance of the inciting allergen, if known. Many school districts are implementing system-wide action plans for children with life-threatening asthma or anaphylaxis. Implementation of these protocols can promote increased awareness and improve the care of children who experience anaphylaxis while in school. 54, 55 Parents should check with their child's school district to see if their school has an action plan in place. Children with a history of anaphylaxis should wear medical alert jewelry (eg, a bracelet) or alternatively keep a medical alert card in their wallet. Additional discharge medications can include oral antihistamines and corticosteroids for up to 72 hours.
Close follow-up with the child's primary care physician and referral to a pediatric allergist are absolutely necessary. Immunotherapy can be effective for some individuals, most notably for those with anaphylaxis to envenomations.
Parents should be given on- 
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Pediatric Anaphylaxis, Lane and Bolte 1. The incidence of anaphylaxis in children and adolescents has been estimated to fall in the range of: a) 1 per 100,000 b) 10 per 100,000 c) 50 per 100,000 d) 100 per 100,000 e) 200 per 100,000 2. The commonest cause of anaphylaxis in children is: a) penicillin b) foods c) latex d) cefaclor e) hymenoptera 3. A father brings his 6-year-old son to the emergency department after the boy became sick on a camping trip. He reports that the child was stung on the neck by a ''bee'' and, approximately 30 minutes later, became red in the face and experienced difficulty breathing and wheezing. Upon your examination, the child has a heart rate of 130/min, respirations of 28/min, blood pressure of 70/40 mm Hg, urticaria on the face and upper trunk, and bilateral wheezing. He weighs 20 kg. Your diagnosis was anaphylaxis, and you administer 0.2 mg of epinephrine, 25 mg of diphenhydramine, and 40 mg of prednisone.
The boy improves dramatically, but he begins to experience difficulty breathing and wheezing 2 hours later. The most likely explanation for the recurrence of symptoms is: a) misdiagnosis of an anaphylactoid reaction b) improper choice of medication c) inadequate dose of medication d) genetic predisposition to atopy e) biphasic reaction 4. The mother of a 2-year-old girl reports that her daughter began wheezing 30 minutes ago after ingestion of a cookie that may have contained peanuts. She also reports that the child had ''splotches'' all over her body. Upon your examination, you find normal vital signs, no rash, and clear lungs. You then review her chart and note that she has presented twice previously with a similar story and an unremarkable examination. Suspecting Munchausen syndrome by proxy, you send blood to the laboratory to determine the level of: a) histamine b) basophils c) eosinophils d) a-1 antitrypsin e) tryptase 
